CagriSema (Cagrilintide B and Semaglutide I)
CagriSema (Cagrilintide B and Semaglutide I) is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
1
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
2
trials recruiting
4
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
Clinical Trials (4)
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4